Arrowhead Research | ARWR - Current Liabilities


Arrowhead Research reported $295.22M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026